All In Biotech

Drug Trial Radar · NCT05688475

A Rollover Study of CC-122

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating CC-122

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Apr 11, 2023

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NCT02417285\]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.

Conditions

  • Non-Hodgkin Lymphoma

Interventions

  • CC-122Drug

    Specified dose on specified days

  • DexamethasoneDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122Time frame: Up to approximately 3 years
  2. Number of deaths for participants who received at least 1 dose of CC-122Time frame: Up to approximately 3 years

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Local Institution - 100

    New York, New York

  • Local Institution - 101

    Nashville, Tennessee

  • Local Institution - 102

    Madison, Wisconsin

  • Local Institution - 300

    Bordeaux, France

  • Local Institution - 301

    Marseille, France

  • Local Institution - 500

    Koto-ku, Tokyo, Japan

  • Local Institution - 400

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.